Publikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Gregorio Marañón (22)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center

    BMC Musculoskeletal Disorders, Vol. 25, Núm. 1

2023

  1. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey'

    Annals of the Rheumatic Diseases

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT

    RMD open, Vol. 9, Núm. 3

  4. Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study

    Rheumatology International, Vol. 43, Núm. 7, pp. 1333-1340

  5. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care

    RMD open, Vol. 9, Núm. 2

  6. The role of ultrasound and FDG-PET/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis

    Modern rheumatology, Vol. 33, Núm. 3, pp. 549-556

2022

  1. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  2. Impact of cardiovascular risk on the diagnostic accuracy of the ultrasound Halo Score for giant cell arteritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  3. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?

    Clinical Rheumatology

  4. Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

  5. Ultrasound intima media thickness cut-off values for cranial and extracranial arteries in patients with suspected giant cell arteritis

    Frontiers in Medicine, Vol. 9

2021

  1. Clinical impact of confinement due to the COVID-19 pandemic on patients with fibromyalgia: A cohort study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3

  2. Radiosynovectomy in routine care: an old tool with modern applications

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  3. Safety in the use of ultrasound in rheumatology during the COVID-19 Pandemic. Spanish Society of Rheumatology positioning paper

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 284-289

  4. Subclavian artery involvement in patients with giant cell arteritis: do we need a modified Halo Score?

    Clinical Rheumatology, Vol. 40, Núm. 7, pp. 2821-2827

  5. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development

    Arthritis Research and Therapy, Vol. 23, Núm. 1

  6. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review

    Rheumatology and Therapy, Vol. 8, Núm. 1, pp. 17-40

2020

  1. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 12, pp. 1544-1549